Member Info for Jimbo1122

How can a share price leap by up to 15% on news of a new CEO and then be reversed in the space of two days with no obvious reason. It was a good appointment but i was a bit concerned that he actually left Teva to retire from working life. The fact that he has this frame of mind suggests to me that he will be lacking the drive needed to advance Hikma through some difficult times. He obviously doesn't need the money or the hassle and he will always have thoughts of leisurely pursuits constantly on his mind--that is a bit worrying.

This share is like a coiled spring. It was released yesterday and shot up 15% at one stage. It's now been wound back down. If we get good news on Advair and end of year results are not too bad then it will be released once again but without the winding back down. Incidentally, an analyst mentioned the fact that a trading statement didn't accompany the CEO announcement does suggest that the results will be in line with expectations which is a good thing.

Disappointed that it fell back so much from today's high of 10.80. On the plus side it still finished up 45p and who wouldn't have settled for that before opening this morning. Hopefully, the fact that it did rise so quickly and easily today should tempt many more buyers to purchase these shares. Let's hope tomorrow is a good day.

I think there will be a temporary dip coming up soon (profit takers) but long term it will keep rising. The great thing now is that even if the end of year figures still show Generics under pressure the reaction will not be as bad because major steps are now being taken to address the matter. It's important to note that Hikma also appointment a new Chief Scientist who has a great reputation but that was largely ignored by the market but could prove to be equally relevant to driving the business forward.

Now up 140p (15%). The shorters must be going mental now.

Fantom--i have reported you to the moderator. Singing is not allowed on this forum (LOL).

Definitely achieveable Fantom. As Ian Dury would say we have "Reasons to be cheerful"

Can you imagine the wealth of knowledge and extensive contacts this new CEO will bring to Hikma. Not tempted to sell because this SP will only go one way now - - - UP.

Big bounce in the last 30mins (up 25p). Probably Deutsche Bank buying back the shares they keep selling - - i wish they would make up their minds.

I notice that Vectura has also shot up this morning (5%). I wonder if news is leaking out that Hikma / Vectura Advair appeal may go in their favour.

Just had a notification from Hikma that final dividend payment date is 24/5/18 (Record date 5/4/18). We won't find out what the actual payment will be until the end of year statement. At least we will be getting a payment due to the fact that Hikma are still profitable.

You're right Aamir, the Generic sector at the moment is untenable. No Pharmaceutical company is going to continue selling drugs in this sector without making a decent margin. Products will start to be withdrawn, prices will rise and companies will start to merge with each other. Hikma themselves did state that the Generic market will improve and it will. Fortunately, Hikma don't rely solely on Generics and will be able to ride the storm better than most. Hikma did also state that more resources will be directed to the areas where margins are much better so at least they seem to be addressing the problem. This share is grossly oversold in fact there is a scale that determines how undervalued a company is where 0 is extremely undervalued and 100 is grossly overvalued - - Hikma is currently sitting at 18.

We have a boaster in our ranks.

Foxykiwi--you will not regret buying at this price and holding long term. The markets do act irrationally at times and they have really excelled themselves on this one.

Hikma, thankfully has a strong balance sheet and good cash generation. There is no chance of them going out of business (any time soon) which obviously gives me some comfort. It is best for things to play out naturally and the Hikma SP will eventually recover. As long as the dividends are unaffected it will just be like a savings account to me.

I will repeat what i said a couple of months ago. Nobody can start a pharmaceutical company from scratch and build it up to what Hikma has now for less than £5 Billion and at least 5-10 years hard graft. Hikma is now extremely likely to be subject to a takeover bid and i don't think it will be limited to one suitor.

Exactly three years ago there were strong rumours that Mylan was preparing to make a £7 Billion plus bid (£35.00 per share) for Hikma. Now we are sitting at £8.50 per share for no good reason except the Advair Generic being delayed. You couldn't make it up.

Thank you Pianista and Soniraman. That makes more sense than Directors selling at a ridiculously low price and the message that would have sent out. The fall today must be solely due to FDA rejecting another Advair application this time from Novartis. That's three Pharmaceutical companies with the most modern manufacturing plants and skilled chemists that are unable to gain approval for a generic version of a drug that has been on the market for over 15 years. You could perhaps understand one or two (at a push) failing at the final hurdle but there's definitely something not right when three are rejected. FDA had better be sure they are not being pressurised into these decisions or they open themselves up to legal action.

News is coming through that the FDA have also denied the Novartis Advair Generic application. You would think that this would boost Hikma (less competition) but the other way of looking at it is that the FDA are playing hardball with this Generic and this may scupper Hikmas appeal. If the Director Dealing is them actually offloading shares then it means two things 1/ They are not exactly confident that things will improve in the near future and 2/ They will not be hard to deal with if any company wishes to take them over.

Can anyone shed some light on the recent Director Share dealings. As usual, it's really difficult to tell if they have bought them or sold them. We are talking about big amounts 6M, 2M and by several Directors.